Abstract
Objective: Analysis of treatment results of myeloma-related renal impairment with regard to hemodialysis treatment and mortality. Design: Retrospective analysis of single center data.
Methods: Analysis of data in registry of monoclonal gammapathies. Patients with newly diagnosed multiple myeloma between June 2007 and June 2015 were included in the study.
Results: Myeloma was newly diagnosed in 443 patients. Renal impairment at the time of diagnosis was found in 101 (22.8 %) patients.
Hemodialysis treatment was started in 58 (13 %) patients. A third of patients treated with bortezomib based regimen recovered renal function.
However, no patient recovered renal function in a group that was treated with regimen without bortezomib. Conclusion: Bortezomib inclusion into treatment regimen in patients with myeloma-related renal failure led to recovery of renal function in a third of patients.
Mortality of patients with myeloma-related renal failure is still very high compared to patients with renal failure due to other causes.